Status:
UNKNOWN
Multimodal Retinal Imaging in the Detection and Follow-up of Alzheimer's Disease
Lead Sponsor:
Universitaire Ziekenhuizen KU Leuven
Conditions:
Alzheimer Disease
Alzheimer Dementia
Eligibility:
All Genders
50-85 years
Brief Summary
Because of a shared ontogenic origin, the retina displays similarities to the brain and spinal cord in terms of anatomy, functionality, response to insult, and immunology. Hence, the retina can be app...
Detailed Description
Alzheimer's disease (AD) is the most common neurodegenerative disorder and the leading cause of dementia worldwide. A growing number of people are surviving into their 80s-90s and the number of AD pat...
Eligibility Criteria
Inclusion
- Between ≥ 50 and ≤ 85 years of age.
- In the opinion of the investigator, the patient is in stable medical condition and willing and able to perform study procedures.
- Patient is fluent in written and verbal Dutch.
- Patient is capable of giving informed consent.
Exclusion
- Patient has a history or current evidence of a neurological disorder, which, in the opinion of the primary investigator, may contribute to the subject's cognitive impairment.
- Patient has a history of large-vessel stroke or evidence of a large-vessel infarction or other focal lesions on baseline MRI scan, which may contribute to the cause of the memory impairment in the opinion of the investigator. Vascular white matter lesions or other signs of microangiopathy will not be considered an exclusion.
- Patient has a history of malignancy ≤ 5 years prior to signing informed consent, except for patients who have undergone potentially curative therapy with no evidence of recurrence for 1 year, and who are deemed at low risk for recurrency by her/his treating physician.
- Patient is currently participating or has participated in a study with an investigational compound within 30 days of signing informed consent.
- Subject has any magnetizable metal prostheses, implants or foreign objects that could pose a hazard during MRI scans.
- Patient has a known history of ocular diseases other than the exception of cataract and/or wearing glasses/contact lenses.
Key Trial Info
Start Date :
March 1 2018
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2025
Estimated Enrollment :
320 Patients enrolled
Trial Details
Trial ID
NCT03466177
Start Date
March 1 2018
End Date
December 31 2025
Last Update
October 10 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
UZ Leuven
Leuven, Vlaams Brabant, Belgium, 3000